Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinial Trials

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease

Sharpening the focus to ‘treating the patient, not the disease’ can lead to a paradigm shift in outcomes

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer

Approximately 136,000 cases of gastric cancer are diagnosed annually in Europe

- PMLiVE

Sanofi/ Regeneron’s Dupixent recommended by CHMP to treat eosinophilic oesophagitis

Patients in a phase 3 trial experienced improvements in their ability to swallow after four weeks

- PMLiVE

New research shows potential to treat kidney disease with common medicines

Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK

- PMLiVE

Retrospective prospective

Looking back at what we learned in 2022 and what the new year may bring

healthcare meeting

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

Wilmington Healthcare

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

UK Government commit £50m to motor neurone disease research

The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links